Nabi Biopharmaceuticals Completes Enrollment for NicVax Vaccine Study Ahead of Schedule
Drug maker Nabi Biopharmaceuticals on Thursday said it has completed enrollment ahead of schedule for its mid-stage study of NicVax, a potential vaccine to treat nicotine addiction and prevent smokers from relapsing.
The company said it finished enrollment for the Phase IIB study three months earlier than previously anticipated, and trial results are expected early in the second quarter of 2007.
The NicVax vaccine is designed to prevent nicotine from entering the brain where it would trigger the release of dopamine, a stimulant that is part of what makes nicotine addictive.
Nabi shares rose 32 cents, or 5.1 percent, to $6.58 in morning trading on the Nasdaq. The stock has traded in a 52-week range of $3.06 to $13.04.
Drug maker Nabi Biopharmaceuticals on Thursday said it has completed enrollment ahead of schedule for its mid-stage study of NicVax, a potential vaccine to treat nicotine addiction and prevent smokers from relapsing.
The company said it finished enrollment for the Phase IIB study three months earlier than previously anticipated, and trial results are expected early in the second quarter of 2007.
The NicVax vaccine is designed to prevent nicotine from entering the brain where it would trigger the release of dopamine, a stimulant that is part of what makes nicotine addictive.
Nabi shares rose 32 cents, or 5.1 percent, to $6.58 in morning trading on the Nasdaq. The stock has traded in a 52-week range of $3.06 to $13.04.
posted by doublezero at
2:01 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home